Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After the Olympics on WRAL: WRAL's Liz McLaughlin breaks down epic comebacks and double downs on the second full day of Olympic competition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
110.32
+0.39 (+0.35%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis Ag ADR
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
28
29
Next >
Fusion Pharmaceuticals is Future Pillar of Cancer Treatment: Analyst
June 23, 2023
Raymond James has initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN) with an Outperform rating and a
Via
Benzinga
Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation
June 22, 2023
Mizuho initiated coverage on Terns Pharmaceuticals Inc (NASDAQ: TERN) with a Buying rating and price target of $16,
Via
Benzinga
Why Shares of Vera Therapeutics Jumped Tuesday
June 20, 2023
The company announced early phase 2 trials information regarding its lead therapy.
Via
The Motley Fool
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
June 19, 2023
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union.
Via
The Motley Fool
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
June 16, 2023
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that
Via
Benzinga
Health Care Company Novartis Announces Merger With Chinook Therapeutics
June 12, 2023
Via
Benzinga
Is Novartis a Good Stock to Buy Right Now?
June 07, 2023
The multinational pharma giant excels as an income play.
Via
The Motley Fool
Looking At Novartis's Recent Unusual Options Activity
June 01, 2023
Via
Benzinga
Avrobio Offloads Gene Therapy Program For Rare Genetic Disorder To Novartis
May 22, 2023
Via
Benzinga
Stock Market Rally Runs Through Hawkish Fed; Adobe, Lennar, Oracle, UnitedHealth In Focus: Weekly Review
June 16, 2023
Stocks kept powering higher despite, but the Nasdaq is looking extended.
Via
Investor's Business Daily
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
June 15, 2023
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.
Via
Investor's Business Daily
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
June 14, 2023
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a
Via
Benzinga
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook
June 12, 2023
Chinook Therapeutics is about to be acquired by Novartis. News of this deal hasn't stopped Muddy Waters from betting against KDNY stock.
Via
InvestorPlace
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
May 04, 2023
Eylea sales fell and missed expectations in the U.S.
Via
Investor's Business Daily
Chinook Therapeutics Launches Almost 60% On Novartis' $3.5 Billion Takeover
June 12, 2023
Novartis will pay $3.5 billion to buy the kidney disease-focused biotech company.
Via
Investor's Business Daily
XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust
June 12, 2023
Find out more about two big winners Monday morning.
Via
The Motley Fool
Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories
June 12, 2023
Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger
Via
Benzinga
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?
June 12, 2023
Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS).
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 12, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
Via
InvestorPlace
Why Are Chinook Therapeutics Shares Trading Higher Today
June 12, 2023
Novartis AG (NYSE: NVS) has agreed to acquire Chinook Therapeutics Inc (NASDAQ: KDNY) for $40 per share in cash,
Via
Benzinga
Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
June 12, 2023
Via
Benzinga
Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories
June 08, 2023
Wall Street Journal
Via
Benzinga
Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations
June 08, 2023
Novartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales over the next five years from launching new products after it spins out of its
Via
Benzinga
Avrobio Stock Jumps On Sale Of Gene Therapy Program To Novartis
May 22, 2023
Shares of clinical-stage gene therapy company AVROBIO, Inc. (NASDAQ: AVRO) are trading higher Monday due to its agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program...
Via
Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Via
Benzinga
Why Is AVROBIO (AVRO) Stock Up 83% Today?
May 22, 2023
AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS).
Via
InvestorPlace
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
May 09, 2023
Via
Benzinga
What's Going On With Immix Biopharma Stock Today
May 03, 2023
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
Via
Benzinga
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
May 03, 2023
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several...
Via
Benzinga
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
May 02, 2023
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.